Craft

Graphite Bio

Stock Price

$22.3

2024-03-22

Market Capitalization

$185.2 M

2024-03-22

Revenue

$19.1 M

FY, 2025

Graphite Bio Summary

Company Summary

Overview
Graphite Bio is a gene-editing company focused on the development of therapies for patients suffering from life-threatening genetic diseases. It offers products candidates to treat sickle cell disease, immunodeficiency syndrome, Gaucher disease, and restore normal adult hemoglobin expression.
Type
Public
Status
Active
Founded
2017
HQ
South San Francisco, CA, US | view all locations
Website
https://graphitebio.com/
Cybersecurity rating
Sectors

Key People

  • Josh Lehrer

    Josh Lehrer, Chief Executive Officer

  • Jerry Cacia

    Jerry Cacia, Chief Technical Officer

  • Jane Grogan

    Jane Grogan, Chief Scientific Officer

  • Christine Garrett

    Christine Garrett, Chief of Staff and Senior Vice President of Operations

LocationsView all

1 location detected

  • South San Francisco, CA HQ

    United States

    279 E Grand Ave. #430

Graphite Bio Financials

Summary Financials

Revenue (Q1, 2026)
$1.9M
Gross profit (Q1, 2026)
$825.0K
Net income (Q1, 2026)
($41.5M)
Cash (Q1, 2026)
$24.8M
EBIT (Q1, 2026)
($44.1M)
Enterprise value
$160.7M

Footer menu